Use of NK-1 receptor antagonist serlopitant in pruritus
US11026920B2 · kind B2 · utility
0Cited by
52References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 2, 2020 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Mar 2, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.